Abstract Background Direct oral anticoagulants (DOACs) have shown a positive benefit-risk
balance in both clinical trials and real-world data, but approximately 2% to 3.5% of patients …

Acute lower gastrointestinal bleeding (LGIB) is a common reason for hospitalization in the
United States and is associated with significant utilization of hospital resources, as well as …

This consensus document is proposed to clinicians to provide the whole spectrum of deep
vein thrombosis management as an update to the 2017 consensus document. New data …

• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

While there is a clear clinical benefit of oral anticoagulation in patients with atrial fibrillation
(AF) and venous thromboembolism (VTE) in reducing the risks of thromboembolism, major …

Intracerebral hemorrhage (ICH) accounts for a disproportionate amount of stroke-related
morbidity and mortality. Although chronic hypertension and cerebral amyloid angiopathy are …

Cardiopulmonary bypass (CPB) has allowed for significant surgical advancements, but
accompanying risks can be significant and must be expertly managed. One of the foremost …

Spontaneous intracerebral hemorrhage is a particularly devastating type of stroke with
greater morbidity and mortality compared with ischemic stroke and can account for half or …

Importance Direct oral anticoagulant (DOAC)–associated intracranial hemorrhage (ICH) has
high morbidity and mortality. The safety and outcome data of DOAC reversal agents in ICH …

Background Andexanet alfa is approved (FDA “accelerated approval”; EMA “conditional
approval”) as the first specific reversal agent for factor Xa (FXa) inhibitor-associated …